Feasibility trial of a transdiagnostic individual lifestyle evaluation and intervention (Lev-i) for health behavior change
PLOS One · 2026
DOI: 10.1371/journal.pone.0339500 ↗Kurz gefasst
Klinische Studie in der Zeitschrift PLOS One, 2026. Verfasst von Douglas Sjöwall und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center of Neurodevelopmental Disorders at Karolinska Institutet (KIND), Department of Women's and Children's Health, Centre for Psychiatry Research, …. Hauptthemen laut MEDLINE: Health Behavior, Life Style, Persons with Disabilities. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stiftelsen Promobilia.
Abstract (Originalsprache)
Purpose
Individuals with disabilities face challenges in adopting and maintaining healthy behaviors. Existing interventions are often diagnosis-specific, profession-bound, and limited to single health behaviors, restricting a broader applicability. This study evaluated the feasibility and acceptability of Lev-individual (Lev-i), a transdiagnostic and interprofessional intervention designed to promote health behaviors among individuals with disabilities.
Method
This feasibility study was conducted in an outpatient disability healthcare setting, involving 25 adult participants with long-term disabilities. Lev-i consists of three structured sessions focusing on goal setting, motivational strategies, and behavior change techniques that can be used across ten health domains. Data on treatment completion, acceptability and secondary outcomes was collected through self-reports for participants and professionals before, during, and after the intervention.
Results
The treatment completion rate was 23 out of 25 (92%), with high treatment satisfaction (M = 3.61 out of maximum 4). Participants reported significant increases in treatment credibility and expectancy of change (6.93 pre, 8.27 post, p < .01), as well as high treatment satisfaction. Professionals rated the intervention as relevant and feasible, though many comments indicated a need for simplification of the study protocol and clearer intervention materials. No serious adverse events were reported. For secondary outcomes, goal attainment scores indicated that participants on average reached their goals. Also, there was a significant improvement in dietary habits ( p < .05, d = 0.55), and a non-significant trend toward increased physical activity ( d = 0.39).
Conclusion
Findings suggest that Lev-i is a feasible and acceptable intervention for promoting health behaviors among individuals with disabilities. However, further refinements may enhance feasibility for both patients and professionals before conducting a randomized controlled trial. ClinicalTrials.gov (NCT05889936).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Center of Neurodevelopmental Disorders at Karolinska Institutet (KIND), Department of Women's and Children's Health, Centre for Psychiatry Research, Karolinska Institutet & Region Stockholm, Stockholm, Sweden.
- Habilitation and Health, Stockholm Health Care Services, Region Stockholm, Sweden.
- Division of Psychology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Douglas Sjöwall
Förderung
- Stiftelsen Promobilia
Zitieren
APA
Sjöwall, D., Brar, A., Fladvad, A., Långh, U., & Hirvikoski, T. (2026). Feasibility trial of a transdiagnostic individual lifestyle evaluation and intervention (Lev-i) for health behavior change. PLOS One. https://doi.org/10.1371/journal.pone.0339500
Vancouver
Sjöwall D, Brar A, Fladvad A, Långh U, Hirvikoski T. Feasibility trial of a transdiagnostic individual lifestyle evaluation and intervention (Lev-i) for health behavior change. PLOS One. 2026. doi:10.1371/journal.pone.0339500
BibTeX
@article{Sjwall2026,
author = {Sjöwall, Douglas and Brar, Annika and Fladvad, Anna and Långh, Ulrika and Hirvikoski, Tatja},
title = {Feasibility trial of a transdiagnostic individual lifestyle evaluation and intervention (Lev-i) for health behavior change},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0339500}
}
EUVIMED